Guardian Pharmacy Services (GRDN) Projected to Post Quarterly Earnings on Monday

Guardian Pharmacy Services (NYSE:GRDN) is expected to post its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $354.1490 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Guardian Pharmacy Services Stock Performance

Shares of GRDN stock opened at $28.16 on Monday. The firm has a fifty day moving average of $26.51 and a 200-day moving average of $23.71. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -18.53 and a beta of 0.96. Guardian Pharmacy Services has a 52-week low of $17.29 and a 52-week high of $30.39.

Institutional Investors Weigh In On Guardian Pharmacy Services

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in Guardian Pharmacy Services during the second quarter worth $43,000. State of Wyoming bought a new stake in shares of Guardian Pharmacy Services during the 2nd quarter worth about $58,000. JPMorgan Chase & Co. grew its stake in Guardian Pharmacy Services by 48.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after buying an additional 1,956 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Guardian Pharmacy Services by 37.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,981 shares of the company’s stock valued at $149,000 after acquiring an additional 1,914 shares during the period. Finally, State of Tennessee Department of Treasury bought a new position in Guardian Pharmacy Services in the 2nd quarter valued at about $186,000.

Analyst Upgrades and Downgrades

GRDN has been the subject of a number of research analyst reports. Wall Street Zen raised Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Oppenheimer started coverage on Guardian Pharmacy Services in a report on Friday, October 10th. They set an “outperform” rating and a $30.00 price objective on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Guardian Pharmacy Services in a report on Wednesday, October 8th. Finally, Truist Financial lifted their price target on shares of Guardian Pharmacy Services from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 26th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.